Theriva Biologics Investor Relations Material

Theriva Biologics Inc, formerly Synthetic Biologics, Inc., is a clinical-stage company that develops therapeutics to treat diseases in areas of high unmet need. The company uses its synthetic biology platform to create human proteins for use in biologics and also licenses this proprietary platform for the development of novel products from third parties. The company's lead drug product candidate is rindopepimut, which is in Phase III clinical trials for the treatment of glioblastoma multiforme and for the prevention of recurring breast cancer in patients with bone metastases. Synthetic Biologics' rindopepimut has received orphan drug designation from the Food and Drug Administration for both indications.